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Abstract 
Background: The monitoring of Plasmodium falciparum sensitivity to anti-malarial drugs is a necessity for effective 
case management of malaria. This species is characterized by a strong resistance to anti-malarial drugs. In Senegal, the 
first cases of chloroquine resistance were reported in the Dakar region in 1988 with nearly 7% population prevalence, 
reaching 47% by 1990. It is in this context that sulfadoxine–pyrimethamine temporarily replaced chloroquine as first 
line treatment in 2003, pending the introduction of artemisinin-based combination therapy in 2006. The purpose of 
this study is to assess the ex vivo sensitivity to different anti-malarial drugs of the P. falciparum population from Pikine.
Methods: Fifty-four samples were collected from patients with non-complicated malaria and aged between 2 and 
20 years in the Deggo health centre in Pikine in 2014. An assay in which parasites are stained with 4′, 6-di-amidino-
2-phenylindole (DAPI), was used to study the ex vivo sensitivity of isolates to chloroquine, amodiaquine, piperaquine, 
pyrimethamine, and dihydroartemisinin. High resolution melting was used for genotyping of pfdhps, pfdhfr, pfmdr1, 
and pfcrt genes.
Results: The mean  IC50s of chloroquine, amodiaquine, piperaquine, dihydroartemisinin, and pyrimethamine were, 
respectively, 39.44, 54.02, 15.28, 2.23, and 64.70 nM. Resistance mutations in pfdhfr gene, in codon 437 of pfdhps gene, 
and an absence of mutation at position 540 of pfdhps were observed. Mutations in codons K76T of pfcrt and N86Y 
of pfmdr1 were observed at 51 and 11% population prevalence, respectively. A relationship was found between the 
K76T and N86Y mutations and ex vivo resistance to chloroquine.
Conclusion: An increase in sensitivity of isolates to chloroquine was observed. A high sensitivity to dihydroarte-
misinin was observed; whereas, a decrease in sensitivity to pyrimethamine was observed in the parasite population 
from Pikine.
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Background
Malaria is a parasitic disease which was responsible for 
nearly 429,000 deaths worldwide in 2015. More than 92% 
of these deaths occur in Africa in children [1]. Children 
under 5 years and pregnant women are among those 
most vulnerable to malaria. This can be explained by the 
fact that in malaria-endemic areas, after years of expo-
sure, non-sterilizing immunity develops that is protec-
tive against severe malaria. Pregnant women tend to lose 
this acquired immunity due to the immune-suppression 
which occurs during pregnancy, and studies have shown 
that placental parasitaemia in these individuals is higher 
than those of peripheral blood [2], putting both mother 
and child at high risk. Many tools are currently avail-
able to fight malaria in these vulnerable groups such as 
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intermittent preventive treatment of pregnant women 
with sulfadoxine–pyrimethamine (SP) [3, 4] and sea-
sonal malaria chemoprevention (SMC) for children 
under 5 years of age in areas with seasonal transmission 
of malaria [5]. Currently in Senegal, for SMC in children, 
the drug regimen of choice is SP-amodiaquine. Amodi-
aquine is also used in combination with artesunate for 
treatment of uncomplicated malaria. Cross-resistance 
has been observed between amodiaquine and chloro-
quine. Thus, it would be important to monitor the sen-
sitivity of parasites to SP to ensure the effectiveness of 
these preventive combination treatments. A good cor-
relation between in  vivo resistance to SP and in  vitro 
resistance has been characterized as well as a strong asso-
ciation between in vivo resistance and single nucleotide 
polymorphisms in pfdhps (Plasmodium falciparum dihy-
dropteroate synthetase) and pfdhfr (P. falciparum dihy-
drofolate reductase) genes [6–10]. In vitro resistance to 
pyrimethamine is associated with the mutation at codon 
S108N of pfdhfr gene, whereas the resistance to sulfadox-
ine is associated with the mutation K540E of the pfdhps 
gene. In West Africa, triple mutations at codons N51I, 
C59R and S108N of the pfdhfr gene and the mutation 
G437A/T in the pfdhps gene are frequently observed. In 
Senegal, the quadruple mutation representing the triple 
mutation of the pfdhfr gene plus the mutation G437A/T 
in the pfdhps is also frequently observed [11–13]. In East 
Africa, a further mutation in pfdhps at codon K540E has 
been described [9]. This quintuple mutation is highly 
associated with a therapeutic failure to SP. WHO rec-
ommends that in areas where the quintuple mutation 
reaches greater than 50% population prevalence that 
SP use should be abandoned for chemoprevention of 
malaria [2].
The monitoring of amodiaquine, chloroquine, pipe-
raquine, and dihydroartemisinin sensitivity is a clear pri-
ority in the fight against malaria. As amodiaquine is used 
for prevention and treatment of malaria in Senegal, it is 
important to determine if there is a decrease of sensitiv-
ity of P. falciparum population to this drug and if this 
decrease is related to the past (cross-resistance between 
amodiaquine and chloroquine) or current amodiaquine 
use. The overall objective of this study is to assess the 
ex  vivo sensitivity of P. falciparum isolates from Pikine 
to SP, amodiaquine, chloroquine, piperaquine, and 
dihydroartemisinin.
Methods
Sample collection
In 54 children aged between 5 and 20 years of age who 
came for consultation at the Deggo health centre in 
Pikine in 2014, both venous blood and filter paper were 
collected. These children suffered from non-compli-
cated malaria with confirmation by drop thick and thin 
smears. Informed consent by the child and or guardian 
was requested before any samples were taken. The study 
protocol was validated by the Human Subjects Commit-
tee of Tulane University and the Ethics Committee of the 
Ministry of Health of Senegal. The work is funded by the 
International Centres of Excellence for Malaria Research, 
(ICEMR) West Africa (U19AI089696).
Ex vivo assays
Drug preparation
Pyrimethamine (Sigma), chloroquine diphosphate salt, 
amodiaquine hydrochloride, dihydroartemisinin, and 
piperaquine were reconstituted with dimethyl sulfox-
ide (DMSO). The dilution was performed with the non-
supplemented Roswell Park Memorial Institute Medium 
(RPMI). Twofold serial dilutions were performed with 
the non-supplemented Roswell Park Memorial Institute 
Medium (RPMI). The highest drug concentrations plated 
were 750  nM for chloroquine, 500  nM for piperaquine, 
100 nM for amodiaquine, 50 nM for dihydroartemisinin, 
and 295,056 nM for pyrimethamine. Each drug concen-
tration was plated in duplicate. Plates were frozen at 
−20 °C until required.
Culture and CI50 determination
The tubes of venous blood collected for DAPI test were 
transported to Aristide Le Dantec Hospital within 6 h of 
blood draw. The plasma was removed by centrifugation 
(2500g for 10  min). The pellet was then washed twice 
with unsupplemented RPMI by centrifugation at 2500g 
for 5 min. Parasitaemia was adjusted to between 0.4 and 
1% and haematocrit was adjusted to 2%. The parasitae-
mia and haematocrit adjusted parasite mixture was dis-
tributed on the previously dosed 96-well drug plates and 
incubated in the presence of gas (94%  N2, 5%  CO2, 1% 
 O2) [14] at 37  °C. After 48  h of incubation, the growth 
of parasite in positive control wells specifically plated 
for microscopic evaluation was checked. The assays 
was determined to be complete when parasites had re-
invaded as new rings. Plates were frozen at −20 °C until 
reading and reading was performed for all plates at once.
For staining and reading the DAPI assay, 100  µl of 
membrane lysis buffer containing the molecule DAPI was 
distributed to each well. After a 30 min incubation, plates 
were centrifuged 4000g for 10 min, washed with PBS, and 
fluorescence was measured using a Fluoroskant Ascent. 
 IC50 values were calculated using graph Pad Prism soft-
ware version 5. Reference clone 3D7, sensitive to all anti-
malarial drugs tested, was used for each batch of drug 
plates as a positive control.
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DNA extraction and single nucleotide polymorphism typing
Parasitic DNA was extracted using the QIAamp DNA 
Blood Mini kit (Qiagen) according to manufacturer 
instructions. Codons 51, 59–108 of the pfdhfr gene, 436, 
437, 540, and 613 of pfdhps, 76 of pfcrt and 86 of pfmdr1 
were genotyped by HRM [12]. Glass capillaries were used 
with a 10 µl final volume. All PCR were performed using 
2.5X LightScanner master mix (Biofire), with forward 
primers at a final concentration of 0.05 µM, reverse prim-
ers at a final concentration of 0.2 µM (asymmetric PCR), 
allele specific probes at a final concentration of 0.2 µM, 
and 1 µl of genomic DNA, as previously described [12]. 
Standard software included with the instruments was 
used for unlabelled probe analysis to visualize melting 
peaks based on different melting temperatures, indicative 
of different base pairs, and compared with controls to call 
alleles for a given assay.
Statistical analysis
The Graph-pad Prism Software version 5 was used to cal-
culate the  IC50 value for all drugs for each parasite isolate 
tested. For each codon position, the distribution of  IC50s 
were compared using the Mann–Whitney U test. The test 
is significant if the P value is less than 0.05.
Fig. 1 Distribution of  IC50 value among parasites collected in Pikine in 2014 and tested again Chloroquine (a), Piperaquine (b), Amodiaquine (c), 
Dihydroartemisinin (d) and Pyrimethamine (e). Horizontal lines indicate the geometric mean of  IC50 value in red with the 95% CI. For all panels  IC50 
high value is not represented
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Results
Ex vivo sensitivity to chloroquine, amodiaquine, 
piperaquine, dihydroartemisinin, and pyrimethamine
Good sensitivity of the 3D7 reference strain to chloro-
quine (22.05  nM) was observed. The geometric mean 
 IC50 for all isolates for chloroquine, amodiaquine, pipe-
raquine, dihydroartemisinin, and pyrimethamine were 
35.44, 54.02, 15.28, 2.23, and 64.70  nM, respectively 
(Fig. 1).
Prevalence of point mutations of pfdhps, pfdhfr, pfcrt, 
and pfmdr1 genes
Mutations at codons 51, 59 and 108 of dhfr were highly 
prevalent with 100, 95 and 96% observed, respectively. 
For codon 437, a proportion of 44% with mixed wild 
type and mutant (2%) was observed. No mutation was 
observed at the 540 position of pfdhps gene. For codon 76 
of the pfcrt gene 51% of mutations and 6% of mixed was 
found. About the codon 86 of pfmdr1, the mutation rate 
amounted to 11% (Table 1).
All strains that contained the mutation N86Y of pfmdr1 
gene were mutant or mixed at codon K76T of pfcrt. For 
pfdhps and pfdhfr triple, quadruple and quintuple muta-
tion were observed at 95, 39 and 0% prevalence, respec-
tively (Table 2).
Association between genotype and phenotype
The ex vivo resistance to chloroquine has been found to 
be linked to the mutation at codon K76T of pfcrt gene 
and N86Y of pfmdr1 (Table  3). For amodiaquine, the 
observation was that the values found for the mutant 
strains on these codons were higher but not significantly 
different. In our study, no relationship was found between 
the mutation K76T and N86Y and the decrease in ex vivo 
sensitivity to piperaquine, dihydroartemisinin and 
pyrimethamine. High prevalent of mutation on codon 51, 
59 and 108 of the pfdhfr gene was found, probably related 
to the decrease in sensitivity to pyrimethamine.
Discussion
It is essential to have effective anti-malarial drugs to 
fight malaria. Artemisinin combination therapies were 
introduced as first-line therapy in this context. However, 
growing resistance to ACT has been observed in South-
east Asia: in Cambodia in 2006, Myanmar and Thailand 
in 2008, and Vietnam in 2009, and Laos in 2013 [15]. 
The rationale for monitoring resistance phenotypically 
by the in vitro method is that several anti-malarial drugs 
can be tested at the same time, and the evolution of the 
sensitivity or resistance of parasite populations to drugs 
either in use or no longer in use can be studied. The study 
of molecular markers of resistance informs the level 
of resistance of the Plasmodium population to drugs at 
the genetic level. This will result in better understand-
ing of which drugs to monitor in  vivo, which combina-
tions to avoid, and those that can be used effectively for 
the management of malaria. In Senegal, pyrimethamine 
combined with sulfadoxine is used for intermittent pre-
ventive treatment for pregnant women. Further SP, plus 
Table 1 Prevalence of  point mutation of  pfdhps, pfdhfr, 
pfcrt, and pfmdr1 genes at positions 51, 59, 108, 437, 540, 
76, and 86
Gene Codon Allele Prevalence
Pfdhfr N51I I 100% (51/51)
C59R R 96% (49/51)
S108N N 98% (50/51)
Mixte 2% (1/51)
Pfdhps A437G G 44% (24/54)
G/A 2 (1/54)
K540E K 100% (54/54)
E 0%
Pfcrt K76T T 51% (28/540)
Mixte 6% (3/54)
Pfmdr1 N86Y Y 11%
Mixte 0%
Table 2 Prevalence of  mutant haplotype in  pfdhps 
and pfdhfr
Haplotype Prevalence
Triple mutation 95% (40/42)
Quadruple mutation 39% (15/38)
Quintuple mutation 0% (0/44)
Table 3 Correlation between  mutation at  Pfcrt codon 
K76T and  Pfmdr1 codon N86Y and  sensitivity to  chloro-
quine, amodiaquine, piperaquine, dihydroartemisinin, 
and pyrimethamine
P value is significant when less than 0.05
GM: geometric mean, IC50: half maximal inhibitory concentration, WA: wild allele, 
MA: mutant allele
Compound Codon GM of IC50 
(nM) for WA
GM of IC50 
(nM) for MA
P value
Chloroquine K76T 13.86 74.15 0.0195
N86Y 33.90 391.2 0.0279
Amodiaquine K76T 9.924 10.47 0.0539
N86Y 9.417 20.69 0.5290
Piperaquine K76T 56.16 46.45 0.9370
N86Y 27.15 58.00 0.8155
Dihydroartemisinin K76T 2.139 1.773 0.4614
N86Y 2.165 1.906 0.7727
Pyrimethamine K76T 11,596 4981 0.8366
N86Y 2.165 3.377 0.4605
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amodiaquine is used for preventive seasonal treatment 
for children under 5 years old in areas with high trans-
mission of malaria [16]. Chloroquine was eliminated 
in Senegal in 2003 following cases of resistance in  vivo 
[17]. Piperaquine combined with dihydroartemisinin is 
used for the third-line treatment of non-complicated 
malaria. For molecular markers of resistance, the muta-
tion on codons K76T of pfcrt gene and N86Y of pfmdr1 
has been demonstrated to be associated with resistance 
to chloroquine [18–22]. Resistance to amodiaquine is 
associated with the N86Y mutation and cases of cross-
resistance between amodiaquine and chloroquine have 
been observed. For pyrimethamine, the mutation on 
codon S108N is strongly associated with resistance [23]. 
In  vivo resistance of P. falciparum to chloroquine has 
been confirmed in Pikine, Moulomp (Casamance) and 
Fatick [24]. Indeed, the emergence of resistance to chlo-
roquine in Senegal were reported in 1988 in Dakar with 
5.7% therapeutic failure [25]. These cases then increased 
to 47.5% in 1990 and 25–30% in 1992 in Pikine [26], lead-
ing to the withdrawal of chloroquine for treatment of 
non-complicated malaria in Senegal in 2003. However, 
amodiaquine, which has some cross-resistance with chlo-
roquine, is always used in combination for the treatment 
or prevention of malaria. In Dakar in 2010 a geometric 
mean of 41.63 nM for chloroquine and 19.4 nM for amo-
diaquine was found with another ex vivo technique [13]. 
At Pikine, an in vitro sensitivity study conducted in 2000 
showed 31% of resistance to chloroquine with a geomet-
ric mean of 272 nM [27]. In 2001, a geometric mean of 
135  nM was registered [28]. Prevalence of mutation of 
51% on codon K76T of pfcrt and 11% on the N86Y of 
pfmdr1 gene was recorded in 2014.
The prevalence of the 76T allele in isolates from Pikine 
was 72.4% when chloroquine was used (2000–2003), 
47.16% during the period of the use of amodiaquine-SP 
for first-line treatment (2004–2005) and 59.46% with 
ACT used between 2006 and 2009. N86Y mutation had 
decreased between 2005 and 2009 and it was about 20% 
in 2009 [29]. A selection of N86 and K76 alleles were 
noted in Thiès, another region in Senegal, in 2013 [30]. 
The results of this study have shown that the mutation 
on codon N86Y was related to the decrease in sensi-
tivity to chloroquine. For amodiaquine, the geomet-
ric mean of the isolates with the mutation N86Y was 
higher compared to isolates with wild-type allele, but 
the difference was not significant. For piperaquine, no 
relationship between genotype and  IC50 was observed. 
An association was found between the presence of the 
76T allele and the decrease in sensitivity to chloroquine 
(p = 0.0195) but not to amodiaquine (0.0539) and pipe-
raquine (0.9370). A decrease in ex  vivo sensitivity and 
an increase in the prevalence of the N86Y mutation 
relationship was not significantly found with amodi-
aquine (p =  0.5290) and the geometric mean for pipe-
raquine was very low compared to that found in other 
countries [30–34]. These compounds are currently used 
in combination with dihydroartemisinin for piperaquine, 
SP and artesunate for amodiaquine. Good ex  vivo sen-
sitivity of isolates to dihydroartemisinin was found, 
implying continued effectiveness of one of the partner 
drugs of ACT used in the treatment of non-complicated 
malaria in Pikine.
Used since 2003 in Senegal, first as temporary replace-
ment of chloroquine for the treatment of non-compli-
cated malaria, SP is now used for preventive treatment 
of malaria. The results showed low ex vivo sensitivity of 
isolates to pyrimethamine. This was accompanied by a 
high prevalence of mutations in codons N51I, C59R and 
S108N of the pfdhfr gene. A strong presence of muta-
tion on codon S108N (67 and 24%) and 51/59 (40 and 
20%) were recorded, respectively, for Thiès in 2003 and 
Pikine in 2002. At Pikine, 65% (N51I), 61% (C59R) and 
78% (S108N) of mutation was found [35]. These results 
suggest that resistance to pyrimethamine emerged 
before the introduction of the SP association. The dou-
ble mutation 437/540 of the pfdhps gene has been dem-
onstrated as being related to resistance to sulfadoxine 
[10]. Ex  vivo sensitivity to sulfadoxine of isolates has 
not been studied. However, an absence of mutation on 
codon K540E and high prevalence of mutation at codon 
G437A/T has been recorded, which confirms the effi-
cacy of sulfadoxine. On the other hand, studies revealed 
that triple mutation 108–59–51 is strongly associated 
with resistance to SP in African isolates [36] and that 
the presence of the double mutation 437/540 indicates 
a high risk of treatment failure in SP [9]. An increase 
of triple mutation and quadruple mutation in Pikine 
was noted [35], but the quintuple mutation was absent. 
However, mutation of 2.12% at codon 540 in pfdhfr was 
found in Dakar [36].
Conclusion
Monitoring the sensitivity of P. falciparum populations 
to anti-malarial drugs is a necessity for effective malaria 
case management. An increase in the sensitivity of iso-
lates to chloroquine Good efficacy of dihydroartemisinin 
amodiaquine and piperaquine and decrease in sensitivity 
to pyrimethamine were observed.
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